The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Bank of America Corp. (BAC), ...

It maintains a strong balance sheet with no debt and ... believes Biogen's new products like Leqembi, Skyclarys and Zurzuvae can help revive growth. Flow Control Division Drives Flowserve (FLS ...

New York, USA, March 03, 2025 (GLOBE NEWSWIRE) -- LEQEMBI Market Sales Reflect Growing Confidence in Disease-Modifying Alzheimer’s Treatments| DelveInsight LEQEMBI (lecanemab) has significant ...

The company confirmed this morning that NICE has taken the "unusual decision" to hold a third appraisal committee meeting as part of its ongoing evaluation of Leqembi (lecanemab), which was turned ...

The milestone was reached as sales of Leqembi reached €200 million in Eisai fiscal year 2024 (April 2024 - Match 2025). The event entitles BioArctic to a €10 million payment. Leqembi is the ...

New York, USA, March 03, 2025 (GLOBE NEWSWIRE) -- LEQEMBI Market Sales Reflect Growing Confidence in Disease-Modifying Alzheimer’s Treatments| DelveInsight LEQEMBI (lecanemab) has significant market ...

For Eisai and Biogen, the CHMP’s decision to stick by its previous call now punts the final approval verdict for Leqembi back to the European Commission (EC), which is the ultimate authority on ...

In August, NICE declined to recommend Biogen and Eisai’s Leqembi (lecanemab) for reimbursement. Three months later, NICE followed with the same decision on Lilly’s Kisunla (donanemab).

In a big win that underscored the growing prominence of indepedent animation, Gints Zibalodis’ “Flow,” the moving dialog-free tale of a solitary cat’s journey as it learns to survive after ...

Eisai and Biogen have completed their rolling biologics license application in the US for a subcutaneous formulation of Alzheimer's disease therapy Leqembi previously delayed by the FDA on ...